{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T06:49:27Z","timestamp":1775112567971,"version":"3.50.1"},"reference-count":92,"publisher":"Oxford University Press (OUP)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1093\/eurheartj\/ehr373","type":"journal-article","created":{"date-parts":[[2011,10,22]],"date-time":"2011-10-22T01:14:38Z","timestamp":1319246078000},"page":"2922-2932","source":"Crossref","is-referenced-by-count":187,"title":["Antiplatelet agents for the treatment and prevention of atherothrombosis"],"prefix":"10.1093","volume":"32","author":[{"given":"Carlo","family":"Patrono","sequence":"first","affiliation":[]},{"given":"Felicita","family":"Andreotti","sequence":"additional","affiliation":[]},{"given":"Harald","family":"Arnesen","sequence":"additional","affiliation":[]},{"given":"Lina","family":"Badimon","sequence":"additional","affiliation":[]},{"given":"Colin","family":"Baigent","sequence":"additional","affiliation":[]},{"given":"Jean-Philippe","family":"Collet","sequence":"additional","affiliation":[]},{"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[]},{"given":"Dietrich","family":"Gulba","sequence":"additional","affiliation":[]},{"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[]},{"given":"Steen","family":"Husted","sequence":"additional","affiliation":[]},{"given":"Steen Dalby","family":"Kristensen","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Morais","sequence":"additional","affiliation":[]},{"given":"Franz-Josef","family":"Neumann","sequence":"additional","affiliation":[]},{"given":"Lars Hvilsted","family":"Rasmussen","sequence":"additional","affiliation":[]},{"given":"Agneta","family":"Siegbahn","sequence":"additional","affiliation":[]},{"given":"Philippe-Gabriel","family":"Steg","sequence":"additional","affiliation":[]},{"given":"Robert F.","family":"Storey","sequence":"additional","affiliation":[]},{"given":"Frans","family":"Van de Werf","sequence":"additional","affiliation":[]},{"given":"Freek","family":"Verheugt","sequence":"additional","affiliation":[]}],"member":"286","published-online":{"date-parts":[[2011,10,20]]},"reference":[{"key":"key\n\t\t\t\t20170515130537_EHR373C1","first-page":"166","article-title":"Expert Consensus document on the use of antiplatelet agents","volume":"25","year":"2004","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170515130537_EHR373C2","doi-asserted-by":"crossref","first-page":"199S","DOI":"10.1378\/chest.08-0672","article-title":"Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)","volume":"133","year":"2008","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170515130537_EHR373C3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20170515130537_EHR373C4","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists\u2019 (ATT) Collaboration","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170515130537_EHR373C5","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515130537_EHR373C6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jacc.2008.10.047","article-title":"Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays","volume":"53","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170515130537_EHR373C7","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials","volume":"332","year":"2006","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20170515130537_EHR373C8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/35051599","article-title":"Identification of the platelet ADP receptor targeted by antithrombotic drugs","volume":"409","year":"2001","journal-title":"Nature"},{"key":"key\n\t\t\t\t20170515130537_EHR373C9","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0037-1614133","article-title":"Identification and biological activity of the active metabolite of clopidogrel","volume":"84","year":"2000","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170515130537_EHR373C10","first-page":"21","article-title":"Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease","volume":"29","year":"2008","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170515130537_EHR373C11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCULATIONAHA.109.853069","article-title":"New P2Y12 inhibitors","volume":"121","year":"2010","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515130537_EHR373C12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jacc.2009.12.071","article-title":"Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration. A systematic meta-analysis","volume":"56","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170515130537_EHR373C13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nm.2281","article-title":"Paraoxonase-1 is a major determinant of clopidogrel efficacy","volume":"17","year":"2011","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t20170515130537_EHR373C14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1527-3466.2007.00027.x","article-title":"Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile","volume":"25","year":"2007","journal-title":"Cardiovasc Drug Rev"},{"key":"key\n\t\t\t\t20170515130537_EHR373C15","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.jacc.2008.07.068","article-title":"Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo","volume":"52","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170515130537_EHR373C16","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/eurheartj\/ehp159","article-title":"Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial","volume":"30","author":"for the TRITON-TIMI 38 Investigators","year":"2009","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170515130537_EHR373C17","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/0091270009343005","article-title":"Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans","volume":"50","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t20170515130537_EHR373C18","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1111\/j.1538-7836.2010.04020.x","article-title":"Thromboxane antagonism with terutroban in peripheral arterial disease: the TAIPAD study","volume":"8","author":"on behalf of the TAIPAD Investigators","year":"2010","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20170515130537_EHR373C19","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/eurheartj\/ehp296","article-title":"P2Y12 inhibitors: differences in properties and mechanism of action and potential consequences for clinical use","volume":"30","year":"2009","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170515130537_EHR373C20","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease. The ONSET\/OFFSET study","volume":"120","year":"2009","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515130537_EHR373C21","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1538-7836.2009.03527.x","article-title":"Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP-induced receptor signalling and platelet aggregation","volume":"7","year":"2009","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20170515130537_EHR373C22","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/j.1538-7836.2005.01377.x","article-title":"Protease-activated receptors in hemostasis, thrombosis and vascular biology","volume":"3","year":"2005","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20170515130537_EHR373C23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1254\/jphs.08R06FM","article-title":"Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease","volume":"108","year":"2008","journal-title":"J Pharmacol Sci"},{"key":"key\n\t\t\t\t20170515130537_EHR373C24","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(09)60230-0","article-title":"Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double blind, placebo controlled phase II study","volume":"373","author":"for the TRA-PCI Investigators","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170515130537_EHR373C25"},{"key":"key\n\t\t\t\t20170515130537_EHR373C26"},{"key":"key\n\t\t\t\t20170515130537_EHR373C27","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/eurheartj\/ehq320","article-title":"Double-blind, placebo-controlled phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease","volume":"31","author":"on behalf of the J-LANCELOT Investigators","year":"2010","journal-title":"Eur Heart J."},{"key":"key\n\t\t\t\t20170515130537_EHR373C28","doi-asserted-by":"crossref","first-page":"234S","DOI":"10.1378\/chest.08-0673","article-title":"New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)","volume":"133","year":"2008","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170515130537_EHR373C29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","article-title":"European Stroke Prevention Study: II. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke","volume":"143","year":"1996","journal-title":"J Neurol Sci"},{"key":"key\n\t\t\t\t20170515130537_EHR373C30","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(06)68734-5","article-title":"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial","volume":"367","author":"The ESPRIT Study Group","year":"2006","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170515130537_EHR373C31","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jstrokecerebrovasdis.2009.07.010","article-title":"Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials","volume":"18","year":"2009","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"key\n\t\t\t\t20170515130537_EHR373C32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCINTERVENTIONS.109.880179","article-title":"Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study","volume":"3","year":"2010","journal-title":"Circ Cardiovasc Interv,"},{"key":"key\n\t\t\t\t20170515130537_EHR373C33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","article-title":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patients data from randomised trials","volume":"377","year":"2011","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170515130537_EHR373C34","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170515130537_EHR373C35","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0735-1097(01)01164-0","article-title":"Ticlopidine versus aspirin after myocardial infarction (STAMI) trial","volume":"37","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170515130537_EHR373C36","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1056\/NEJM198308183090703","article-title":"Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a veterans administration cooperative study","volume":"309","year":"1983","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515130537_EHR373C37","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1056\/NEJM198511283132201","article-title":"Aspirin, sulfinpyrazone, or both in unstable angina","volume":"313","year":"1985","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515130537_EHR373C38","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","article-title":"Aspirin, heparin, or both to treat acute unstable angina","volume":"319","year":"1988","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515130537_EHR373C39","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)92336-G","article-title":"Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease","volume":"336","author":"The RISC Group","year":"1990","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170515130537_EHR373C40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/01.CIR.82.1.17","article-title":"Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial","volume":"82","year":"1990","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515130537_EHR373C41","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"CURE Trial Investigators","year":"2001","journal-title":"New Engl J Med"},{"key":"key\n\t\t\t\t20170515130537_EHR373C42","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial","volume":"288","author":"for the CREDO Investigators","year":"2002","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170515130537_EHR373C43","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"for the CLARITY-TIMI 28 Investigators","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515130537_EHR373C44","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"for the COMMIT Collaborative Group","year":"2005","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170515130537_EHR373C45","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","volume":"360","author":"The ACTIVE Investigators","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515130537_EHR373C46","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/eurheartj\/ehn416","article-title":"Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology","volume":"29","author":"ESC Committee for Practice Guidelines (CPG)","year":"2008","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170515130537_EHR373C47","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1093\/eurheartj\/ehq277","article-title":"Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"31","author":"ESC Committee for Practice Guidelines EACTS Clinical Guidelines Committee Document Reviewers","year":"2010","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170515130537_EHR373C48","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJMoa1001266","article-title":"Duration of dual antiplatelet therapy after implantation of drug-eluting stents","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515130537_EHR373C49","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"on behalf of the MATCH Investigators","year":"2004","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170515130537_EHR373C50","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"CHARISMA Investigators","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515130537_EHR373C51","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"for the TRITON-TIMI 38 Investigators","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515130537_EHR373C52","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"for the PLATO Investigators","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515130537_EHR373C53","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMp0907122","article-title":"Weighing benefits and risks\u2014the FDA's review of prasugrel","volume":"361","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515130537_EHR373C54","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jacc.2009.03.083","article-title":"Antithrombotics in acute coronary syndromes","volume":"54","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170515130537_EHR373C55","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization","volume":"336","author":"EPILOG Investigators","year":"1997","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515130537_EHR373C56","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials","volume":"359","year":"2002","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170515130537_EHR373C57","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/jama.1997.03550060055036","article-title":"Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention","volume":"278","year":"1997","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170515130537_EHR373C58","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1093\/eurheartj\/ehl334","article-title":"A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50279 patients at risk for coronary artery disease","volume":"27","year":"2006","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170515130537_EHR373C59","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2796.2005.01477.x","article-title":"Low-dose aspirin for secondary cardiovascular prevention\u2014cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation\u2014review and meta-analysis","volume":"257","year":"2005","journal-title":"J Intern Med"},{"key":"key\n\t\t\t\t20170515130537_EHR373C60","doi-asserted-by":"crossref","first-page":"299S","DOI":"10.1378\/chest.08-0675","article-title":"The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)","volume":"133","year":"2008","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170515130537_EHR373C61","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/eurheartj\/ehn104","article-title":"The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomised and observational studies","volume":"29","year":"2008","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170515130537_EHR373C62","first-page":"194","article-title":"The effect of low-dose acetylsalicylic acid on bleeding after transurethral prostatectomy-a prospective, randomized, double-blind, placebo-controlled study","volume":"34","year":"2000","journal-title":"Scand J Urol Nephrol"},{"key":"key\n\t\t\t\t20170515130537_EHR373C63","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/bja\/aem209","article-title":"Perioperative antiplatelet therapy: a case for continuing therapy in patients at risk of myocardial infarction","volume":"99","year":"2007","journal-title":"Br J Anesthesia"},{"key":"key\n\t\t\t\t20170515130537_EHR373C64","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/S0195-668X(03)00485-8","article-title":"Predictors of major bleeding in acute coronary syndromes","volume":"24","year":"2003","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170515130537_EHR373C65","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","year":"2006","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515130537_EHR373C66","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/eurheartj\/ehr204","article-title":"Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the working group on thrombosis of the European Society of Cardiology","volume":"32","year":"2011","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170515130537_EHR373C67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2011.02.039","article-title":"Bleeding avoidance strategies consensus and controversy","volume":"58","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170515130537_EHR373C68","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/eurheartj\/ehq021","article-title":"Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis","volume":"31","author":"on behalf of the REACH Investigators","year":"2010","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170515130537_EHR373C69","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.jacc.2009.09.076","article-title":"A risk score to predict bleeding in patients with acute coronary syndromes","volume":"55","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170515130537_EHR373C70","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/CIRCULATIONAHA.108.828541","article-title":"Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the ACC\/AHA Guidelines) Bleeding Score","volume":"119","year":"2009","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515130537_EHR373C71","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a Consensus Report from the Bleeding Academic Research Consortium (BARC)","volume":"123","year":"2011","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515130537_EHR373C72","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.109.878017","article-title":"Prognostic modelling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the acute catheterization and urgent intervention triage strategy trial","volume":"121","year":"2010","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170515130537_EHR373C73","first-page":"CD002042","article-title":"Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170515130537_EHR373C74","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/jama.292.13.1555","article-title":"Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes","volume":"292","year":"2004","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170515130537_EHR373C75","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jacc.2005.06.072","article-title":"The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative","volume":"46","author":"CRUSADE Investigators","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170515130537_EHR373C76","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/eurheartj\/ehm161","article-title":"Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes","volume":"28","author":"Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology","year":"2007","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170515130537_EHR373C77","doi-asserted-by":"crossref","first-page":"670S","DOI":"10.1378\/chest.08-0691","article-title":"Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)","volume":"133","author":"American College of Chest Physicians","year":"2008","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170515130537_EHR373C78","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515130537_EHR373C79","first-page":"678","article-title":"Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man","volume":"71","year":"1983","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20170515130537_EHR373C80","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa042087","article-title":"Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515130537_EHR373C81","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.cgh.2006.04.019","article-title":"Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications","volume":"4","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170515130537_EHR373C82","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jacc.2005.01.045","article-title":"Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects","volume":"45","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170515130537_EHR373C83","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.clpt.2006.05.004","article-title":"Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease","volume":"80","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20170515130537_EHR373C84","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515130537_EHR373C85","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1093\/eurheartj\/ehl489","article-title":"A double-blind, randomised study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days","volume":"28","year":"2007","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170515130537_EHR373C86","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"CURRENT-OASIS 7 Investigators","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515130537_EHR373C87","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7326\/0003-4819-152-2-201001190-00009","article-title":"International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding","volume":"152","author":"International Consensus Upper Gastrointestinal Bleeding Conference Group","year":"2010","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170515130537_EHR373C88","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.jacc.2010.09.010","article-title":"ACCF\/ACG\/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF\/ACG\/AHA 2008 expert document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use","volume":"56","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170515130537_EHR373C89","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515130537_EHR373C90","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1056\/NEJMp0806848","article-title":"Prasugrel in clinical practice","volume":"361","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515130537_EHR373C91","doi-asserted-by":"crossref","first-page":"630S","DOI":"10.1378\/chest.08-0720","article-title":"Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)","volume":"133","year":"2008","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170515130537_EHR373C92","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus Clopidogrel in acute coronary syndromes in relation to renal function. Results from the platelet inhibition and patient outcomes (PLATO) trial","volume":"122","year":"2010","journal-title":"Circulation"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/32\/23\/2922\/17049431\/ehr373.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T11:09:10Z","timestamp":1560856150000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-lookup\/doi\/10.1093\/eurheartj\/ehr373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,20]]},"references-count":92,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2011,10,20]]},"published-print":{"date-parts":[[2011,12]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehr373","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,20]]}}}